Halberd’s 2nd Proprietary Antibody Against SARS-COV-2 Spike Protein Demonstrates Neutralizing Affinity 20 Times Greater

By |2021-03-01T20:05:18-05:00March 2nd, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, March 2, 2021 – Halberd Corp. (OTC PINK:HALB) has recently produced a proprietary monoclonal antibody that has at least 20 times greater neutralizing affinity than their original antibody against the SARS-COV 2 Spike protein. Dr. Reyes, Halberd’s Chief Technical Officer, indicated, “Our latest results indicate increased specificity of our second antibody, which ...